Seeking Alpha
16 May 2026, 14:37 UTC · 18w ago
Verdict
Headline takes no side. We score CLB +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 71% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Coloplast now trades at a historically low sub-18x P/E and offers a 5.76% dividend yield.
So whatA historically cheap valuation and high yield for a quality defensive name strongly attracts value and income investors, providing significant support for share price appreciation.
More positive than 99% of claims this week
Recent setbacks include a Kerecs acquisition write-down, product recalls, and regulatory shifts.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 95% of claims this week
Coloplast is projected to deliver 12–13% annualized growth until 2028E.
More positive than 85% of claims this week
The analyst issued a buy rating with a new price target of 490 DKK based on a re-based 20x P/E.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
Despite recent setbacks, the company maintains a buy rating due to strong fundamentals and an attractive valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−17.4%
Price is moving against the score
$10.80 vs $13.07 close before publication (May 15) · not market-adjusted
CLB chart →
